Research and development expenses for the quarter ended March 31, 2019, were $31.3 million, compared to $33.4 million for the comparable period in 2018. The decrease was primarily due to lower costs from the progression of certain AR101 clinical trials offset by higher contract manufacturing costs to support clinical development and regulatory activities.
Wednesday, May 8, 2019
Zogenix reports Q1 EPS (83c), consensus (83c)
As of March 31, the company had $480.7M in cash, cash equivalents, and marketable securities, compared to $514.2M at December 31, 2018.
Adverum Biotechnologies reports Q1 EPS (23c), consensus (27c)
Revenue, consisting of revenue from collaborative research, was $0.0 million the three months ended March 31, 2019, compared to $0.2 million for the same period in 2018. Revenue decreased as no research activities were performed under collaboration agreements for the three month period in 2019. Cash, cash equivalents and short-term investments were $189.5 million as of March 31, 2019, compared to $205.1 million as of December 31, 2018. Adverum expects this quarter-end cash position to fund operations into 2021.
Collegium Pharmaceutical reports Q1 EPS (29c), consensus (24c)
Reports Q1 revenue $74.52M, consensus $70.82M.
Subscribe to:
Posts (Atom)